A patient's severe hypothyroidism from neoadjuvant nivolumab required a one-month surgical delay to stabilize thyroid levels before anesthesia. This highlights a seemingly manageable side effect as a critical barrier to timely, curative-intent surgery, underscoring the need for vigilant monitoring of endocrinopathies.

A common clinical observation is that patients who develop significant immune-related toxicities, like colitis or pneumonitis, are frequently the same ones who experience the most profound and durable responses to checkpoint inhibitor therapy.

Nurses can proactively educate patients that if ocular side effects occur, they will likely manifest around the second cycle, between days 10 and 14. This specific timing helps manage patient anxiety and ensures prompt reporting and intervention.

A critical reason patients stop ADC treatments is the burden of side effects like skin toxicity or GI issues, not just disease progression. This underscores the urgent need to develop ADCs with better safety profiles, enabling patients to stay on effective therapy longer.

When debating immunotherapy risks, clinicians separate manageable side effects from truly life-altering events. Hypothyroidism requiring a daily pill is deemed acceptable, whereas toxicities like diabetes or myocarditis (each ~1% risk) are viewed as major concerns that heavily weigh on the risk-benefit scale for early-stage disease.

The side effect profile of capivasertib is front-loaded. Key toxicities like diarrhea and rash appear quickly, leading to the majority (63%) of drug discontinuations occurring within the first three months. This highlights a critical window for proactive management and patient education to improve adherence.

The onset of ocular symptoms from mervituximab is highly predictable, almost always starting between days 10 and 14 of the second treatment cycle. Proactively warning patients about this specific timeline can reduce their anxiety if and when symptoms appear.

Patients receiving systemic immunotherapy for advanced skin cancer are still at high risk for developing new, low-risk primary skin cancers. Medical oncologists should not act as default dermatologists; ongoing co-management is crucial to identify and treat these new lesions while the patient is on systemic therapy.

Clinicians can differentiate side effects based on their profile: "-itis" symptoms (colitis, pneumonitis) suggest immunotherapy, while cytopenias and neuropathy point to chemotherapy. Response to steroids is a key diagnostic clue for immune-related events.